Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about
Online ISSN 3007-2387
Print ISSN 3007-2379

Advanced Trends in Cellular Therapies for Leukemia and Myeloma

Muhammad Junaid Ramzan
BS Medical Laboratory Sciences, Superior University, Lahore
Email: su91-bmlsm-f22-037@superior.edu.pk

Taha Saleem
Lecturer, Faculty of Allied Health Sciences, Superior University, Lahore

Author Details

Keywords: Cell-Therapy, CAR-T, Leukemia, Multiple Myeloma, Immunotherapies, NK-cells, Gene Therapies

Received on 10 Apr 2026
Accepted on 25 Apr 2026
Published on 10 May 2026

Corresponding E-mail & Author*:

Muhammad Junaid Ramzan
BS Medical Laboratory Sciences, Superior University, Lahore
Email: su91-bmlsm-f22-037@superior.edu.pk

Abstract

This paper aims to critically discuss the current developments, clinical uses, and new trends of cellular therapies to leukemia and multiple myeloma and their mechanisms, therapeutic possibilities, and the challenges. This study has been done as a narrative review by following a systematic search of the published works. Electronic databases such as PubMed, Google Scholar, Science Direct and Springer Link were searched using relevant articles. Articles that were published in 2015, and 2026 were identified. The screening and analysis of data were done rationally to cellular therapies like CAR-T cells, natural killer cells, or T-cell receptor-engineered therapies. Major findings reveal that CAR-T cell therapy has shown a high level of efficiency in the treatment of relapsed and refractory leukemia and multiple myeloma, and a high remission rate. New technologies, such as dual-target CAR-T cells, gene-editing technologies, combination therapies, and so forth, have continued to improve the outcomes of therapies. The study concludes that cellular therapies have important scope in the treatment of hematological malignancies offering tailored and personal treatments. Ongoing studies and technological developments are prerequisite to solve the current issues and become more accessible to obtain better clinical outcomes in the future.

Introduction

The hematological malignancies such as leukemia, multiple myeloma is the representative of a heterogeneous group of cancers that occur due to abnormal growth and development of hematopoietic cells. The disorders pose a significant clinical challenge and have a great impact on morbidity and mortality in the global population. In Leukemia, there occurs an uncontrolled proliferation of immature white blood cells in the bone marrow and peripheral circulation and in multiple myeloma, there occurs malignant growth of the plasma cells resulting in bone destruction, lymph node failure, anemia and kidney problems. Regardless of the improvement of diagnostic measures and supportive therapy, the prognosis of most patients is poor, especially in cases of a relapse and resistance. These malignancies have traditionally been treated using conventional treatment methods, inclusive of chemotherapy, radiotherapy and hematopoietic stem cell transplantation. Even though the survival rates have been enhanced by these methods, they are usually known to be limited with high adverse effects, high non-specific cytotoxicity, and resistance to the drugs. Moreover, a large

percentage of patients have a recurrence of the disease, which implies the necessity of more effective and personalized treatment methods (Zhao et al., 2018; Pasquini et al., 2022).

Over the past few years, the use of cellular therapies has become an innovative change in cancer treatment as it gives a very specific and personalized approach to treatment. These treatments involve the use of immune cells naturally able to do so or engineered to do so. In comparison to conventional therapies, cellular therapies induce tumor-specific antigens thus causing less harm to normal tissues and enhancing therapeutic results. This changed paradigm of immunotherapy has had a tremendous impact on the treatment landscape of hematological malignancies.

Chimeric antigen receptor T-cell (CAR-T) therapy has been one of the many cellular therapies that has attracted a lot of attention considering its significant success in clinical practice. CAR-T therapy is a genetic engineering technology that entails the production of T lymphocytes that have been genetically altered to produce synthetic receptors which identify distinct tumor-associated antigens like CD19 and B-cell maturation antigen (BCMA). When infused, the engineered cells selectively capillary suing the cancer cells and can generate cytotoxic immune responses. It has been proven to be effective in clinical studies with high remission rates among patients with relapsed or refractory leukemia and multiple myeloma.

Other cellular methods besides CAR-T therapy, including natural killer (NK) cell therapy and T-cell receptor (TCR)-engineered therapy are also actively pursued. NK cells are respondent of the innate immune system which has the capacity to recognize and destroy tumor cells without undergoing any sensitization hence are a desirable therapy with reduced possibility of causing severe side effects. The development of CAR-NK cells has additionally boosted their anti-tumor efficacy and tolerance to clinical use. Likewise, TCR-engineered therapies can be used to target intracellular tumor antigens expressed through the major histocompatibility complex, thus increasing the set of malignancies that can be targeted.

The emerging new technologies of molecular biology and genetic engineering have also made great contributions towards the development of cellular therapies. CRISPR/Cas9 gene editing and similar methods enable direct editing of immune cells to enhance their specificity, persistence and immunosuppressive resistance. The innovations have enabled the creation of next-generation cellular medicines, such as dual-target CAR-T cells and allogeneic off-the-shelf, which address some of the constraints of the conventional CAR-T therapy.

The current study is aimed at solving these problems with the help of innovative solutions, such as combination therapies, immune checkpoint modulation, predictive bio-markers to optimize patient selection, and patient treatment outcomes. In addition, the combination of artificial intelligence and computational strategies is likely to be applicable to optimize therapy design and assist in clinical decision-making in the future.

Literature Review

Cellular therapies have been an area of much interest as a sophisticated treatment approach towards hematological malignancies especially leukemia and multiple myeloma. Their mechanisms, clinical outcomes, and limitations have been the focus of many research efforts, and they can transform the treatment of cancer. Carl H. June et al. (2018) indicated that (CAR-T) therapy is one of the greatest advancements in cancer immunotherapy, and its effectiveness has shown remarkable progress in treating B-cell malignancies that develop resistance and recur. Their paper emphasized how T-cells genetically engineered can be targeted specifically to tumor-associated antigens thus leading to better clinical results.

Noopur C. Mishra et al. (2023) described tremendous efficacy of BCMA-targeted CAR-T therapy in patients with multiple myeloma, wherein there was a high response population in persons with a high number of previous treatments.

Ravi Kumar et al. (2022) commented that despite the increases in the survival rates, relapse and drug resistance continue to be a significant issue when it comes to leukemia and myeloma treatment. In line with this, Rebecca L. Siegel et al. (2023) indicated growing cancer burden across the world, signaling that more and more therapeutic methods are necessary. Although CAR-T therapy has demonstrated success in the clinical setting, it is linked to various constraints. Sattva S. Neelapu et al. (2018) found cytokine release syndrome (CRS) and neurotoxicity among the noteworthy negative side effects of CAR-T treatment. Moreover, Renier J. Brentjens et al. (2013) noted such challenges as low persistence of CAR-T cells and tumor antigen resistance that may decrease its effectiveness in the long run.

To address these constraints, recent studies have aimed at enhancing cellular therapies of next generation. As mentioned by Lee et al., (2019), the natural killer (NK) cell therapy is a safer option since it is less prone to severe toxicity, and can eliminate tumor cells without any prior sensitization. Federica Morandi et al. (2021) also wrote about the application of T-cell receptor (TCR)-engineered therapies and dendritic cell-based vaccines in boosting immune response and increasing numbers of tumor antigens in their role. The effectiveness of cellular therapies has been further enhanced thanks to the development of more efficient technologies related to gene-editing.

Theodore L. Roth (2020) showed that CRISPR-based alterations have the potential to increase the functionality, specificity, and durability of T-cells, which in turn would result in the improvement of the therapeutic outcomes. Also, Wierson et al. (2017) demonstrated that these approaches based on a specific target gene insertion can greatly improve CAR-T cell functionality and destruction of tumors. The other important factor that affects success of cellular therapies is the tumor microenvironment.

It was indicated that the immunosuppressive tumor microenvironment can suppress the activity of engineered immune cells by Rebecca C. Sterner and Robert M. Sterner (2022), and thus reduce the effectiveness of therapeutic efficacy. They have pointed out that there was a need to devise ways to counter the effects of immunity and enhance the penetration of cells into the tumor areas. Moreover, essential logistical and economic issues are stumbling blocks on the use of cellular therapies in large scale. According to the study conducted by Marcela V. Maus and Bruce L. Levine (2016), high prices, complicated production regimes, and lack of access support reduces the use of these therapies all over the world. New research is thus trying to come up with allogeneic off-the-shelf cell products to overcome these constraints.

Dawn Swan et al. (2024) indicated that B-cell maturation antigen (BCMA)-based chimeric antigen receptor T-cell (CAR-T) therapy has changed the treatment panorama of multiple myeloma and is currently being utilized earlier in therapy. They report significant patient outcome changes, particularly in instances of relapses and refractory cases. On the same note, Huageng Huang et al. (2024) affirmed that CAR-T therapy is one of the fastest developing immunotherapeutic modalities. Nevertheless, other challenges they have also realized that include limited survival of CAR-T cells, toxicity, and resistance related to microenvironment in tumors limits its maximum clinical application.

Asya Bastrich et al., 2025 further detail the state of the art in CAR-NK therapy for multiple myeloma, emphasizing the advantages of diverse NK cell sources—such as cord blood, peripheral blood, NK-92 cell lines, and iPSC-derived NK cells—that support scalable “off-the-shelf” products. This review highlights expanding target antigens (BCMA, SLAMF7, CD38, GPRC5D) and early clinical data demonstrating

potent cytotoxicity with lower risk of graft-versus-host disease (GvHD) and CRS compared to T-cell products.

Larson et al., 2023 reviewed clinical experiences with CAR-T therapy–associated toxicities across leukemia and myeloma trials, providing detailed insight into cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. The authors emphasized advances in early detection, grading systems, and management protocols that have significantly reduced treatment-related mortality. They concluded that improved toxicity management has expanded the eligibility of cellular therapies to older and more clinically fragile patients.

Larson et al., 2023 reviewed clinical experiences with CAR-T therapy–associated toxicities across leukemia and myeloma trials, providing detailed insight into cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. The authors emphasized advances in early detection, grading systems, and management protocols that have significantly reduced treatment-related mortality. They concluded that improved toxicity management has expanded the eligibility of cellular therapies to older and more clinically fragile patients. Chasov, V., & Rizvanov, A. (2025) discussed the conceptual shift toward next-generation CAR engineering, emphasizing synthetic biology approaches to improve safety and control. Their review highlighted inducible CAR systems, suicide switches, and logic-gated CARs that respond only to specific antigen combinations.

Method of Research

Study Design: The proposed research is a narrative literature review that contains a systematic search component. It is about gathering, appraisal, and critical analysis of already published studies of research that is relevant to the field of cellular therapies in leukemia and multiple myeloma. The research is centered on CAR-T cell therapy, NK cell therapy, TCR-engineered therapy and the innovative-immunotherapeutic options.

Study Settings: This paper is a desk-based academic study meant to be done through online scientific databases. No clinical experiments or laboratory work were done. Electronic resources such as PubMed, ScienceDirect, springer link and Google scholar were used to access literature.

Study Duration: This was carried out in 4 months following the acceptance of the synopsis as stipulated by the undergraduate research guidelines. The time frame encompassed literature search, article screening, data collection, analysis and ultimate completion of thesis.

Sample Size: Since the study is review-based research, the sample size will be a number of the published research studies to be used in the analysis. About 40-60 relevant and suitable research articles and review papers were chosen. There was no statistical formula used to calculate the sample size as it is not a clinical or an experimental study. Rather, it was through a systematic screening and relevancy to the research topic that articles were selected.

Sampling Technique: Article selection was through a non-probability purposive method. Only studies that directly related to cellular therapies in leukemia and multiple myeloma were considered. It was possible to give priority to recent publications (2015-2026), high-frequency articles, and peer-reviewed journals.

Inclusion Criteria: Studies included were the ones that were relevant to cellular therapies in leukemia and multiple myeloma. Peer-reviewed research articles and review papers that were published in the English language were only considered. The

criteria included the inclusion of studies in which key therapies (not exhaustive) like CAR-T cell therapy, natural killer (NK) cell therapy, T-cell receptor (TCR)-engineered therapy and other immunotherapeutic treatments were included. Articles starting in 2015 until 2026 were taken to cover both basic concepts as well as the latest advancements, but mostly prioritize the recent research. Clinical studies and experimental studies were included both clinical and preclinical studies as long as they gave valuable information about the mechanisms, effectiveness, or constraint of cellular treatments.

Exclusion Criteria: Studies were filtered out that were not directly pertinent to leukemia, manifold myeloma, and cellular therapy methods. Duplications, non-peer-reviewed articles, conference abstracts that do not have full texts and those sources that do not have enough data or reliable data were also filtered out. Also, those studies that were published not in English and those ones, which were done about unrelated malignancies and did not need any specific reference to the research subject, were not counted.

Results

Cellular Therapies of Hematological Malignancies Overview

Hematologic diseases Hematologic malignancies are diseases in which the abnormal growth of the controllable hematopoiesis-regulated blood cells is uncontrolled, leading to impaired hematopoiesis and immune defects. The common cases are leukemia and multiple myeloma. Although traditional treatment measures like chemotherapy, radiotherapy, and hematopoietic stem cell transplantation have improved, the greatest clinical issues are relapse and resistance of the disease. Due to these shortcomings, more specialized and efficient methodologies of therapy have been developed. Cellular therapies have become a radical approach in the treatment of cancer providing a more specific and tailored approach. Such treatments are based on immune cells naturally endowed or genetically modified to detect and neutralize cancerous cells. Cellular therapies have a better specificity, less off-target efficiency, and better clinical outcomes, especially in relapsed or refractory cases, as compared with conventional therapies. The ongoing development of immunotherapy and molecular biology has only increased the number of patients, who use cellular therapies could have in the case of hematological malignancies.

CAR-T Cell Therapy:

Mechanism of Action:

Chimeric antigen receptor T-cell (CAR-T) therapy is one of the latest types of cellular immunotherapy. This will entail genetically altering the T lymphocytes of a patient such that they are made to produce artificial receptors that are specific to tumor related antigens. These receptors are formulated of an extracellular domain of antigen binding, a hinge region, a transmembrane domain as well as intracellular domains of signaling which cause T-cell activation and proliferation. Upon infusion, the CAR-T cells associate with antigens that are found on the malignant cells on the surface and this results in the activation of immune signaling pathways and cellular destruction of the tumors. This fulfilling action allows antigen-specific cytotoxicity without the presentation of major histocompatibility complex (MHC), thus increasing the therapeutic activities.

Clinical Applications and the New Developments

CAR-T has already been very successful in treating different hematological malignancies such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. High remission rate has been observed in clinical studies especially in individuals who are not responsive to conventional therapies. According

to the current developments, CAR-T therapy has been used earlier in the treatment regimen, which means that it is gaining clinical significance.[38] Secondly, evolving next-generation of CAR-T cells both on a single target and with dual target has enhanced the effectiveness of the therapy by decreasing chances of antigen escape.[36] There are also promising results of combination therapies with CAR-T cells with immune checkpoint inhibitors or any other treatment options.

Limitations and Challenges

CAR-T therapy has its limitations although it has good results. One of the most frequent and serious adverse effects is cytokine release syndrome (CRS) which occurs due to an excess of immune response. Another, but serious, complication that may impact patient safety is neurotoxicity. Along with being toxic, other issues comprise a short transit of CAR-T cells, tumor heterogeneity, and antigen escape, which may lead to disease relapse.[13, 15] Moreover, expensive treatment, complicated production procedures, and lack of accessibility have limited the use of CAR-T therapy especially in a resource-restricted access environment.

Natural Killer (NK) Cell Therapy

Natural killer (NK) cells are an important constituent of innate immune system, and they have the capability to identify and kill tumor cells without having to be sensitized beforehand. NK cells possess this characteristic that is why they are an appealing substitute to CAR-T cure. NK cell therapy has a number of benefits such as decrease in the toxicity and possibilities of using off-the-shelf. In contrast to CAR-T cells, NK cells do not need an individual approach to the patient, which eases the production, and costs of treatment also decrease. Another recent development has been aimed at increasing the power of the NK cell with the help of genetic engineering and combination therapies, which would result in better anti-tumor reactions . NK cell therapy, however, suffers because of lower persistence, low proliferation and relatively less potent cytotoxic activities, which might affect longer-term effective therapy.

Cell Receptor (TCR) Engineered Therapy

Cell Receptor (TCR) Engineered Therapy is another form of cellular immunotherapy with potential is T-cell receptor (TCR)-engineered therapy. TCR-engineered T cells complement the CAR-T cells, targeting intracellular tumor antigens on MHC molecules, unlike surface antigens. This increases the choice of antigens that can be targeted, as well as the adaptability of the therapy. TCR has demonstrated potential in treating malignancies that have little surface antigen expression. Nevertheless, they depend on MHC compatibility and antigen presentation variability and their efficacy. Also, it is not without the threat of off-target toxicity, and thus their applications are not as widespread as they can be used in clinical settings.

Table 4.1. Comparison of Cellular Therapies

Therapy	Mechanism	Advantages	Limitations
CAR-T	Engineered T cells targeting antigens	High efficacy	CRS, high cost
NK Cells	Innate immune cytotoxicity	Low toxicity	Limited persistence
TCR Therapy	Targets intracellular antigens	Broad targeting	MHC restriction

Use of Gene Editing in Cell Therapies

CRISPR/Cas9 and other gene-editing technologies have also greatly enhanced the sphere of cellular therapies potentially permitting focusing on the precise alteration of immune cells. With these technologies, they are better able to target, increase persistence and decrease immunogenicity of engineered cells. The methods based on CRISPR can be used to insert CAR constructs into particular loci of the genome that leads to the enhancement of T-cell activity and elimination of tumors. The benefits of biomarkers and gene editing to optimize the response to treatment and future clinical outcomes have also been examined recently.

Resistance Mechanisms and Tumor Microenvironment:

The microenvironment of the tumor is essential in influencing the success in cellular therapies. It is a combination of immunosuppressive cells, cytokine, and signaling pathways, which are capable of suppressing the immune cells, as well as stimulating the survival of tumors. With the presence of suppressive factors in the tumor microenvironment, the efficacy of CAR-T and other types of cellular therapies may be decreased and result in resistance to treatment. According to the recent studies, the tumor microenvironment can be targeted by following a combination therapy and immune modulation, which can positively impact the therapeutic outcomes.

Figure 4.1. Interaction of Tumor microenvironment with immune cells



Trends and future outlook:

The cellular therapies of leukemia and multiple myeloma are rapidly evolving due to ongoing developments in immunology, genetic engineering and translational medicine. Recent developments have shown a tendency to move away first-generation therapies to more complex and multifunctional cellular therapies to enhance therapeutic efficacy, safety and accessibility.

The next-generation CAR-T cell therapies are one of the highest emerging trends. These improved constructs have several costimulatory domains, safety switches and gene-editing amendments to boost persistence and minimize toxicity. Multi-target and dual-target CAR-T cells are also under development in a bid to overcome the issue of antigen escape, which is a leading reason why treatment fails.

Conclusion

To sum up, cellular therapies in leukemia and multiple myeloma are expected to be incredibly promising in the future, and innovations are being made to increase effectiveness, safety, and availability. The shift to next-generation engineered cells and combined therapeutic approaches and technologies are likely to considerably

enhance clinical outcomes. Further studies, clinical trials and technical incorporation will be necessary to address the current shortcomings and make cellular therapies a foundation of contemporary cancer treatment. One of the most frequent results of the studies examined is that cellular therapy has recently turned towards the more sophisticated and diversified platform of therapeutic possibilities. Dual intratumor-target CAR-T cells, multi-target CAR-T cells, CAR-NK cell therapy, and TCR-engineered therapies are all next-generation strategies that aim to overcome the heterogeneity in tumors and improve safety profiles. Simultaneously, the process of gene-editing, like CRISPR/Cas9, is enabling a greater number of studies to focus on more specific cellular engineering and the creation of universal or allogeneic off-the-shelf therapy, which has more scalability and accessibility.

References:

Ciurea, S. O., Kongtim, P., Soebbing, D., Trikha, P., Behbehani, G., Rondon, G., ... & Champlin,

R. E. (2022). Decrease post-transplant relapse using donor-derived expanded NK-cells. *Leukemia*, *36*(1), 155-164.

Chasov, V., & Rizvanov, A. (2025). Next-Generation CAR Design: Current Status and

Challenges.

Cui, S., Wang, Y., Gong, Y., Lin, X., Zhao, Y., Zhi, D., ... & Zhang, S. (2018). Correlation of the

cytotoxic effects of cationic lipids with their headgroups. *Toxicology research*, *7*(3), 473-479.

June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T

cell immunotherapy for human cancer. *science*, *359*(6382), 1361-1365.

Larson, R. C., Kann, M. C., Graham, C., Mount, C. W., Castano, A. P., Lee, W. H., ... & Maus,

M. V. (2023). Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. *Nature Communications*, *14*(1), 7509.

Lee, J., Thall, P. F., & Rezvani, K. (2019). Optimizing natural killer cell doses for heterogeneous

cancer patients on the basis of multiple event times. *Journal of the Royal Statistical Society Series C: Applied Statistics*, *68*(2), 461-474.

Maus, M. V., & Levine, B. L. (2016). Chimeric antigen receptor T-cell therapy for the

community oncologist. *The oncologist*, *21*(5), 608-617.

Mishra, A. K., Gupta, A., Dagar, G., Das, D., Chakraborty, A., Haque, S., ... & Singh, M. (2023).

CAR-T-cell therapy in multiple myeloma: B-cell maturation antigen (BCMA) and beyond. *Vaccines*, *11*(11), 1721.

Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., ... & Shpall,

E. J. (2018). Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. *Nature reviews Clinical oncology*, *15*(1), 47-62.

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the

current roadblocks in CAR T cell therapy. *Nature reviews Clinical oncology*, *17*(3), 147-167.

Roth, T. L., & Marson, A. (2021). Genetic disease and therapy. *Annual Review of Pathology:*

Mechanisms of Disease, *16*(1), 145-166.

Sammartano, V., Franceschini, M., Fredducci, S., Caroni, F., Ciofini, S., Pacelli, P., ... &

Gozzetti, A. (2023). Anti-BCMA novel therapies for multiple myeloma. *Cancer Drug Resistance*, *6*(1), 169.

Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. *CA: a*
cancer journal for clinicians, *73*(1), 17-48.

Sterner, R. C., & Sterner, R. M. (2022). Immune effector cell associated neurotoxicity syndrome
in chimeric antigen receptor-T cell therapy. *Frontiers in immunology*, *13*, 879608.

Wierson, W. A., Simone, B. W., WareJoncas, Z., Mann, C., Welker, J. M., Gendron, W. A., ... &
Essner, J. J. (2019). Expanding the CRISPR toolbox with mad7 in zebrafish and human cells. *bioRxiv*, 650515.